{"id":626450,"date":"2022-11-21T15:14:02","date_gmt":"2022-11-21T15:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=626450"},"modified":"2022-11-21T15:14:02","modified_gmt":"2022-11-21T15:14:02","slug":"hemophilia-a-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-biomarin-novo-nordisk-opko-biologics-spark-therapeutics-sangamo-bayer-ultrageny","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/hemophilia-a-market-is-predicted-to-exhibit-remarkable-growth-by-2032-analyzes-delveinsight-key-companies-biomarin-novo-nordisk-opko-biologics-spark-therapeutics-sangamo-bayer-ultrageny_626450.html","title":{"rendered":"Hemophilia A Market is Predicted to Exhibit Remarkable Growth by 2032, Analyzes DelveInsight | Key Companies – Biomarin, Novo Nordisk, OPKO Biologics, Spark Therapeutics, Sangamo, Bayer, Ultrageny"},"content":{"rendered":"
\n
\"Hemophilia<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
The Hemophilia A therapeutic market is anticipated to grow in the coming years owing to the rise in healthcare spending worldwide and the launch of emerging therapies. Major Pharma giants are thoroughly working toward developing new treatment therapies for Hemophilia A to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients affected with Hemophilia A.<\/div>\n

As per DelveInsight estimation, the future of haemophilia treatment is continuing to trend toward extended half-life therapies and more novel approaches, including siRNA, bi-specific antibodies and gene therapy<\/strong>. If these therapies are successfully commercialized, they can transform the current standard of care for Hemophilia A patients.<\/em><\/p>\n

DelveInsight’s “Hemophilia A Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Hemophilia A market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).<\/p>\n

The Hemophilia A market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

\"Hemophilia<\/p>\n

Hemophilia A: An Overview<\/strong><\/p>\n

Hemophilia A is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factor VIII. About 30%<\/strong> of severe Hemophilia A patients develop neutralizing anti-FVIII alloantibodies (inhibitors), which render the FVIII replacement ineffective. The standard of care therapy for patients with inhibitors is to induce immune tolerance with high-dose, high-frequency FVIII and treatment with bypassing agents (e.g. recombinant activated factor VII such as NovoSeven, FEIBA).<\/p>\n

The mainstay treatment option has long been FVIII replacement therapy. Initially, FVIII replacement was accomplished by donated whole blood, subsequently by plasma and currently by recombinant human FVIII (rFVIII) replacement therapies, which revolutionized the treatment of Hemophilia A.<\/em><\/p>\n

Hemophilia A Market – Key Highlights<\/strong><\/p>\n